HistoSonics has received CE Mark approval for its Edison Histotripsy System, clearing the way for commercialization of the noninvasive liver tumor treatment platform across Europe and other markets that recognize the certification. The milestone expands the company’s regulatory reach beyond the United States and supports a broader international rollout of technology designed to destroy targeted tissue without incisions, ionizing radiation, or thermal ablation. HistoSonics plans to introduce the system through selected European clinical centers specializing in liver tumor treatment.
European Commercialization
The approval covers the Edison System for the noninvasive mechanical destruction of liver tumors, including the partial or complete destruction of tumors considered unresectable. CE Mark certification enables HistoSonics to commercialize the device across Europe and may support access in other jurisdictions that recognize European conformity assessments. The company will use a phased launch centered on selected institutions, allowing it to build physician experience and collect additional real-world evidence as adoption expands.
How the Technology Works
Edison uses histotripsy, a form of focused ultrasound that delivers short, high-amplitude pulses to create microscopic bubble clouds at a defined target inside the body. The rapid expansion and collapse of those bubbles mechanically disrupts and liquefies tissue, while diagnostic ultrasound and a robotic arm help physicians define and monitor the treatment area. Unlike thermal ablation, the process does not use heat, and unlike radiation therapy, it does not expose patients to ionizing radiation.
Evidence Behind the Approval
HistoSonics said the CE Mark decision was supported partly by the prospective, single-arm HOPE4LIVER trials conducted at 14 sites in the United States and Europe. The study enrolled 47 patients who were ineligible for, had declined, or had not benefited from standard therapies, and investigators treated 52 primary or metastatic liver tumors. At one year, the peer-reviewed analysis reported local control of 63.4% under the primary imaging assessment and 90% under a post hoc review intended to address the learning curve in interpreting histotripsy images.
Safety and Clinical Limitations
The study recorded six serious device-related adverse effects within 30 days and one nonserious device-related effect after 30 days, although the authors characterized the overall safety profile as favorable. The trial was nonrandomized, included a small and clinically diverse population, and was sponsored by HistoSonics, limiting conclusions about survival and comparative effectiveness. Longer follow-up and broader use will be needed to establish durability and determine how histotripsy should be positioned alongside surgery, thermal ablation, radiation, and systemic therapies.
Regulatory and Strategic Progress
The European authorization follows the U.S. Food and Drug Administration’s De Novo clearance of Edison in October 2023 as a Class II device for nonthermal, mechanical destruction of liver tumors. The FDA indication includes unresectable liver tumors, but the classification does not establish that the device treats a specific disease or improves outcomes such as overall survival. HistoSonics also states that the system should be used only by physicians who complete company-provided training and apply clinical judgment when selecting patients.
The CE Mark gives HistoSonics access to a major new market and introduces another noninvasive option for selected European patients with difficult-to-treat liver tumors. Edison’s mechanical, image-guided approach differentiates it from surgical, thermal, and radiation-based treatments, but its long-term role will depend on stronger comparative and survival evidence. The success of the phased rollout will therefore be measured by hospital adoption, consistent clinical outcomes, careful patient selection, and transparent reporting as experience grows.